Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.73 |
| ▸ | CDC7 | O00311 | 1/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | PAK4 | O96013 | 1/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | PRKCB | P05771 | 1/20 | 0.73 |
| ▸ | INSR | P06213 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 1/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.73 |
| ▸ | PRKACA | P17612 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 1/20 | 0.73 |
| ▸ | JAK3 | P52333 | 1/20 | 0.73 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.73 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.73 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433941 | 0.93 | AURKA (0.69) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433576 | 0.92 | AURKA (0.68) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1434073 | 0.92 | AURKA (0.68) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1434017 | 0.91 | AURKA (0.69) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433639 | 0.91 | AURKA (0.67) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433403 | 0.90 | AURKA (0.66) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1895752 | 0.90 | AURKA (0.66) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433553 | 0.90 | AURKA (0.66) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433855 | 0.90 | AURKA (0.66) | AURKACDC7CHEK1JAK2PAK4 | |
| SCHEMBL1433650 | 0.90 | AURKA (0.71) | AURKACDC7CHEK1JAK2PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | claimed |
| WO-2009138440-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-19 | — | — | WO | claimed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| WO-2009138440-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | AURKA 84/4885CDC7 221/4885CHEK1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.